Show simple item record

dc.contributoren-US
dc.creatorMaruti, Astrid Ayu; Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia
dc.creatorKhamsita, Rahmi; Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia
dc.creator., Suven; Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia
dc.creatorPutri, Dyaningtyas Dewi; Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia
dc.creatorMeiyanto, Edy; Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia
dc.date2011-10-01
dc.date.accessioned2019-10-29T03:15:42Z
dc.date.available2019-10-29T03:15:42Z
dc.identifierhttp://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/639
dc.identifier10.14499/indonesianjpharm0iss0pp265-272
dc.identifier.urihttp://r2kn.litbang.kemkes.go.id:8080/xmlui/handle/123456789/25283
dc.descriptionArecoline, the main alcaloid of Areca cathecuL has been proven to posses cytotoxic  activity  against  various  cancer  cell  lines.  The  research  conducted  to examine  the  cytotoxic  activity  of  arecoline  alone  and  its  combination  with doxorubicin  against  HeLa  cervical  cancer  cell  line.  Single treatment  of arecoline  in  various  concentration  on  HeLa  cancer  cell  were  done  followed  by the  combinational  treatment  with  doxorubicin.  The  cell  viability  as  the parameter  of  cytotoxicity  was  measured  using  MTT  (3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium  bromide)  assay.  The  apoptotic  effect  was  examined  by double staining assay using etidium bromide – acridin orange. Arecoline did not show  potent  cytotoxicity  effect  against  HeLa  since  the  value  of  IC50 is  462µM. The  combinational  treatment  of  arecoline  and  doxorubicin  showed  synergicity with  the  optimum  CI  value  is  0,48  given  by  the  treatment  of  30mM  arecoline combined with 125 nM doxorubicin. The result of this study shows that arecoline has potential  to  be proposed  as  co-chemotherapeutic  agent for  cervical cancer. However, further study on its molecular mechanism needs to be conducted.Key words: arecoline, synergicity, doxorubicin, MTT assay, HeLa cell lineen-US
dc.format
dc.languageeng
dc.publisherFaculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesiaen-US
dc.relationhttp://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/639/512
dc.rightsCopyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY0
dc.rightshttp://creativecommons.org/licenses/by-sa/4.00
dc.sourceIndonesian Journal of Pharmacy; Vol 22 No 4, 2011; 265-272en-US
dc.source2338-9486
dc.source2338-9427
dc.titleSinergisitas efek sitotoksik kombinasi arekolin dan doxorubicin pada sel kanker serviks HeLaen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record